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the treatment of neovascular age-related macular degenerationAge-related macular degeneration (AMD) is the leading cause of
legal blindness worldwide.1 Neovascular AMD (nAMD) is character-
ized by the growth of abnormal choroidal blood vessels beneath the
retinal pigment epithelium and/or sensory retina. Most treatment
strategies developed for nAMD treatment have targeted choroidal
neovascularization (CNV). The pathogenesis of CNV is not
completely understood, although the overexpression of vascular
endothelial growth factor (VEGF) has been recognized as having a
crucial role.2 The blockade of VEGF effectively inhibits the forma-
tion of CNV. Therefore, anti-VEGF therapy has emerged as a prom-
ising therapeutic strategy for the treatment of nAMD.
In this issue of the Taiwan Journal of Ophthalmology, Kato and co-
authors3 contribute a comprehensive review of anti-VEGF therapy
for nAMD. In 2004, the U.S. Food and Drug Administration (FDA)
approved pegaptanib (Macugen; Eyetech Pharmaceuticals, New
York, NY, USA) as the ﬁrst anti-VEGF agent for intravitreal injection
to treat nAMD.4 It is a 28-base RNA aptamer that selectively binds
only the VEGF165 isoform of VEGF-A. This limits its efﬁcacy and
further clinical application. In 2006, ranibizumab (Lucentis; Genen-
tech, South San Francisco, CA, USA) was the second anti-VEGF agent
introduced into the market. It is an antibody fragment that inhibits
all VEGF-A isoforms and was designed speciﬁcally to treat nAMD.
Two landmark clinical studiesdthe Minimally Classic/Occult Trial
of the Anti-VEGFAntibody Ranibizumab in the Treatment of Neo-
vascular Age-Related Macular Degeneration (MARINA) and the
Anti-VEGF Antibody for the Treatment of Predominantly Classic
Choroidal Neovascularization in Age-RelatedMacular Degeneration
(ANCHOR) trialdestablished a paradigm shift in nAMD treat-
ment.5,6 Vision was stabilized in 94% of patients receiving ranibizu-
mab with 40% of the patients experiencing improved vision by at
least three lines. Bevacizumab (Avastin; Genentech, South San
Francisco, CA, USA) is a monoclonal antibody that binds all isoforms
of VEGF-A. In 2004, the FDA approved it for the treatment ofhttp://dx.doi.org/10.1016/j.tjo.2014.01.002
2211-5056/Copyright  2014, The Ophthalmologic Society of Taiwan. Published by Elsemetastatic colon cancer. However, the intravitreal injection of bev-
acizumabwas applied as an off-label use for the treatment of nAMD
worldwide because of its cheaper price. The clinical equivalence of
ranibizumab versus bevacizumab was demonstrated by the results
of the Age-Related Macular Degeneration Treatment Trial (CATT),
which was sponsored by the National Eye Institute of USA.7 The
study results showed that monthly bevacizumab was equivalent
to monthly ranibizumab, and bevacizumab p.r.n. was equivalent
to ranibizumab p.r.n. Ranibizumab p.r.n. was equivalent to monthly
ranibizumab, although the comparison between bevacizumab p.r.n.
and monthly bevacizumab was inconclusive.
Most patients with nAMD respond favorably to the aforemen-
tioned anti-VEGF agents; however, some patients become less
responsive to ranibizumab or bevacizumab after repeated injec-
tions. Tachyphylaxis is a contributing factor. It is deﬁned as a
progressively diminished therapeutic effectiveness to a drug af-
ter repeated administration. Tachyphylaxis has been demon-
strated for bevacizumab and for ranibizumab in the treatment
of nAMD.8
In this issue of the Taiwan Journal of Ophthalmology, Cheng
et al9 report a rapid response to intravitreal aﬂibercept in the
treatment of a patient with nAMD who developed tachyphylaxis
to bevacizumab and ranibizumab. Subretinal ﬂuid (SRF) and
pigment epithelial detachment persisted in spite of 14 bevacizu-
mab and seven ranibizumab injections. After only one injection
of intravitreal aﬂibercept, marked improvement was observed
within 1 week. Four weeks after the ﬁrst aﬂibercept injection,
complete drying of the SRF and marked subsiding of pigment
epithelial detachment were noted and sustained for three consec-
utive monthly injections. In 2011, the FDA approved aﬂibercept
(Eylea; Regeneron, Tarrytown, PA, USA and Bayer HealthCare, Ber-
lin, Germany) as a new anti-VEGF agent for the treatment of
nAMD.10 It is composed of a recombinant soluble decoy receptor
fusion protein that incorporates the second binding domain of the
VEGF receptor-1 and the third binding domain of the VEGF
receptor-2. The binding afﬁnity of aﬂibercept to VEGF was higher
than that of ranibizumab. Two clinical trialsdVEGF Trap-Eye,
Investigation of Efﬁcacy and Safety in Wet AMD (VIEW 1 and
VIEW 2)dshowed that the aﬂibercept treatment groups were
noninferior and clinically equivalent to monthly ranibizumab in-
jections for the primary endpoint.11 In addition, studies suggest
that aﬂibercept may effectively treat patients with refractory
nAMD and persistent ﬂuid, despite repeated intravitreal ranibizu-
mab and/or bevacizumab injections.12,13 Unlike currently avail-
able anti-VEGF agents, aﬂibercept binds all isoform of VEGF-A,vier Taiwan LLC. All rights reserved.
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factor in angiogenesis.14 These characteristics could be a contrib-
uting factor that enables aﬂibercept to treat eyes with nAMD that
are refractory to ranibizumab or bevacizumab.
In conclusion, in the past decade, a very exciting advance in the
treatment of nAMD came with the introduction of anti-VEGF ther-
apy. The advent of anti-VEGF therapy marked a turning point in the
treatment of nAMD. The usefulness of bevacizumab, ranibizumab,
or aﬂibercept is supported by large-scale randomized clinical trials.
However, the optimal treatment regime remains controversial.15
Furthermore, these beneﬁcial results come with a drawback.
Most anti-VEGF agents are expensive. The cost of frequent clinical
visits and examinations is burdensome for the patients, physicians,
and health providers (e.g., government). Repeated intravitreal in-
jections raise the risk of endophthalmitis, retinal detachment, vit-
reous hemorrhages, and cataracts. A sustained rise in intraocular
pressure has also been reported after repeated injections of anti-
VEGF agents.16 The battle to conquer CNV in nAMD seems to have
a long way to go. We look forward to seeing more anti-VEGF agents
developed with a higher potency and longer duration for the treat-
ment of nAMD.References
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